DB05967InvestigationalSmall molecule
Investigated for use/treatment in cancer/tumors (unspecified) and liver cancer.
- Mechanism
- Curator reviewed
CRS-100 is a bacteria-based immune therapy that targets liver metastases. Liver metastases arise from a number of cancers, including colon and pancreas cancers. Despite recent advances, metastasized colorectal and pancreatic cancers remain significant unmet medical needs.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified) and liver cancer.Curator reviewed
- Code names
- ANZ 100 · CRS-100
Resolves to
Compound
Targets
What you can answer from here — as of June 12, 2020
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with ANZ-100, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account